Caphosol

EUSA Pharma has launched a new artificial saliva preparation, Caphosol, for the management of dry mouth and oropharynx as well as mucositis due to radiation or high-dose chemotherapy.

Caphosol comprises two separately packaged aqueous solutions, a phosphate solution and a calcium solution which, when combined, form a solution supersaturated with respect to both calcium and phosphate ions. It is an electrolyte solution designed to moisten, lubricate and clean the oral cavity including the mucosa of the mouth, tongue and oropharynx.

Caphosol can be used four to 10 times daily and patients should avoid eating or drinking for at least 15 minutes after use.

View Caphosol drug record

Further information: EUSA Pharma

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

MHRA restricts indications for quinolone antibiotics following EU-wide safety review

New restrictions and precautions for use have been...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.